NCT05363072View on ClinicalTrials.gov

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

CompletedOBSERVATIONAL
Enrollment

1,112

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

June 8, 2022

Study Completion Date

June 8, 2022

Conditions
Renal Cell CancerRenal Cell CarcinomaCancer of KidneyCancer of the KidneyKidney CancerKidney NeoplasmsRenal Cancer
Trial Locations (1)

00330

Pfizer Finland, Helsinki

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05363072 - A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. | Biotech Hunter | Biotech Hunter